TB
MCID: MYC084
MIFTS: 69

Mycobacterium Tuberculosis 1 (TB)

Categories: Cardiovascular diseases, Endocrine diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases

Aliases & Classifications for Mycobacterium Tuberculosis 1

MalaCards integrated aliases for Mycobacterium Tuberculosis 1:

Name: Mycobacterium Tuberculosis 1 57
Tuberculosis 57 12 75 53 59 55 43 3 15 72 33
Tuberculosis, Susceptibility to 57 13 6
Tuberculoma 44 72
Tb 53 48
Mycobacterium Tuberculosis, Susceptibility to, 1 57
Kochs Disease 53
Mtbs1 57

Classifications:



External Ids:

Disease Ontology 12 DOID:399
OMIM 57 607949
MeSH 44 D014375
SNOMED-CT 68 15202009
ICD10 33 A15-A19
MESH via Orphanet 45 D014376
UMLS via Orphanet 73 C0041296
Orphanet 59 ORPHA3389
UMLS 72 C0041295 C0041296

Summaries for Mycobacterium Tuberculosis 1

MedlinePlus : 43 Tuberculosis (TB) is a disease caused by bacteria called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes, or talks. If you have been exposed, you should go to your doctor for tests. You are more likely to get TB if you have a weak immune system. Symptoms of TB in the lungs may include A bad cough that lasts 3 weeks or longer Weight loss Loss of appetite Coughing up blood or mucus Weakness or fatigue Fever Night sweats Skin tests, blood tests, x-rays, and other tests can tell if you have TB. If not treated properly, TB can be deadly. You can usually cure active TB by taking several medicines for a long period of time.

MalaCards based summary : Mycobacterium Tuberculosis 1, also known as tuberculosis, is related to miliary tuberculosis and pleural tuberculosis, and has symptoms including fever, pruritus and snoring. An important gene associated with Mycobacterium Tuberculosis 1 is CD244 (CD244 Molecule), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Calcium carbonate and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include brain, lungs and lymph nodes, and related phenotypes are fever and fatigue

Disease Ontology : 12 A primary bacterial infectious disease that is located in lungs, located in lymph nodes, located in pericardium, located in brain, located in pleura or located in gastrointestinal tract, has material basis in Mycobacterium tuberculosis, which is transmitted by droplets released into the air when an infected person coughs or sneezes.

NIH Rare Diseases : 53 Tuberculosis (TB) is a contagious and often severe airborne disease caused by the TB bacterium, Mycobacterium tuberculosis. TB typically affects the lungs, but other organs of the body may be involved, as well. Not everyone who is infected with the TB bacterium becomes sick. TB bacterial infections only become "active disease" if the immune system can't stop them from growing. Classic signs and symptoms of active TB can include cough, weight loss, fever, night sweats, hemoptysis, chest pain, and fatigue. Symptoms involving areas of the body other than the lungs vary depending on which organ(s) are affected. TB is usually treated with a regimen of medications taken over a long period of time (often six to twelve months).

CDC : 3 Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease. If not treated properly, TB disease can be fatal.

Wikipedia : 75 Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria.... more...

More information from OMIM: 607949

Related Diseases for Mycobacterium Tuberculosis 1

Diseases in the Mycobacterium Tuberculosis 1 family:

Mycobacterium Tuberculosis 2 Mycobacterium Tuberculosis 3

Diseases related to Mycobacterium Tuberculosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2117)
# Related Disease Score Top Affiliating Genes
1 miliary tuberculosis 35.5 TNF IL12RB1 IFNG ADA
2 pleural tuberculosis 35.3 TNF IFNG ADA
3 pericardial tuberculosis 35.1 IL10 IFNG ADA
4 extrapulmonary tuberculosis 34.8 TLR2 SLC11A1 IL10 IFNGR1 IFNG ADA
5 abdominal tuberculosis 34.6 IL12RB1 ADA
6 tuberculous meningitis 34.4 TNF TLR2 ADA
7 tuberculous peritonitis 33.9 TNF IFNG ADA
8 lung disease 33.4 TNF TLR2 IL17A IL10
9 mycobacterium tuberculosis, susceptibility to infection by 33.4 SLC11A1 MTBS1
10 mycobacterium fortuitum 33.4 IL12RB1 IFNGR1 HSPD1
11 nontuberculous mycobacterial lung disease 33.4 TNF TLR2 SLC11A1
12 buruli ulcer 33.2 SLC11A1 IL4 IL10 IFNG
13 melioidosis 33.2 TNF TLR2 IL10 IFNG
14 orofacial granulomatosis 33.2 TNF IL4 IL10 IFNG
15 human immunodeficiency virus type 1 33.1 TNF IL10 IFNG CD209 ADA
16 aspergillosis 33.0 TNF TLR2 IL4 IL10 IFNG CD209
17 sarcoidosis 1 32.3 TNF SLC11A1 IL12RB1 IFNG
18 pleurisy 32.3 TNF IFNG ADA
19 acquired immunodeficiency syndrome 32.2 TNF IL10 IFNG
20 immune deficiency disease 32.2 IL4 IL12RB1 IL10 IFNGR1
21 meningitis 32.2 TNF TLR2 IL10 IFNG ADA
22 peritonitis 32.1 TNF TLR2 IL10 ADA
23 osteomyelitis 32.0 TNF IL10 IFNGR1 IFNG
24 pericarditis 32.0 TNF IFNG ADA
25 leprosy 3 31.9 TNF TLR2 SLC11A1 IL10 IFNG HSPE1
26 lymphadenitis 31.8 TNF SLC11A1 IL12RB1 IL10 IFNGR1 IFNG
27 uveitis 31.8 TNF IL4 IL17A IL10 IFNG
28 candidiasis 31.8 IL17A IL10 IFNG
29 human immunodeficiency virus infectious disease 31.8 TNF IL10 IFNG
30 brucellosis 31.7 TNF SLC11A1 IL4 IL10 IFNG
31 arthritis 31.7 TNF IL17A IL10 IFNG
32 otitis media 31.6 TNF TLR2 IL4 IL10
33 measles 31.6 TLR2 IL4 IFNG CD209
34 typhoid fever 31.5 TNF SLC11A1 IFNGR1 IFNG
35 hematopoietic stem cell transplantation 31.5 TNF IL10 IFNG
36 inflammatory bowel disease 31.5 TNF TLR2 IL4 IL17A IL10 IFNG
37 bacterial infectious disease 31.5 TNF TLR2 SLC11A1 IL17A IL10 IFNG
38 autoimmune disease 31.5 TNF IL4 IL17A IL10 IFNG HSPD1
39 scleritis 31.4 TNF IL4 IFNG
40 toxic shock syndrome 31.4 TNF TLR2 IL4 IL10 IFNG
41 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.4 IL17A IL10 IFNG HSPD1
42 panuveitis 31.4 TNF IL17A IL10
43 neuritis 31.4 TNF IL4 IFNG
44 nocardiosis 31.4 IL12RB1 HSPD1
45 bone inflammation disease 31.4 TNF IL4 IL17A IL10 IFNG
46 toxoplasmosis 31.4 TNF TLR2 IL4 IL10 IFNG
47 ulcerative colitis 31.4 TNF IL17A IL10 IFNG
48 tetanus 31.3 IL4 IL10 IFNG
49 severe acute respiratory syndrome 31.3 TNF IFNG CD209
50 endocarditis 31.3 TNF TLR2 IL10 HSPD1

Graphical network of the top 20 diseases related to Mycobacterium Tuberculosis 1:



Diseases related to Mycobacterium Tuberculosis 1

Symptoms & Phenotypes for Mycobacterium Tuberculosis 1

Human phenotypes related to Mycobacterium Tuberculosis 1:

59 32
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
2 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
3 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
4 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
5 abnormal lung morphology 59 32 frequent (33%) Frequent (79-30%) HP:0002088

Clinical features from OMIM:

607949

UMLS symptoms related to Mycobacterium Tuberculosis 1:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Mycobacterium Tuberculosis 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 ADA CD244 CISH IFNG IFNGR1 IL10
2 digestive/alimentary MP:0005381 10.13 ADA IFNG IFNGR1 IL10 IL17A IL4
3 immune system MP:0005387 10.13 ADA CD244 CISH IFNG IFNGR1 IL10
4 endocrine/exocrine gland MP:0005379 10.1 ADA CISH IFNG IFNGR1 IL10 IL17A
5 liver/biliary system MP:0005370 9.86 ADA IFNG IFNGR1 IL10 IL4 INHA
6 neoplasm MP:0002006 9.7 IFNG IFNGR1 IL10 INHA SLC11A1 TLR2
7 respiratory system MP:0005388 9.56 ADA CISH IFNG IL10 IL17A IL4
8 skeleton MP:0005390 9.28 ADA IFNG IFNGR1 IL10 IL17A IL4

Drugs & Therapeutics for Mycobacterium Tuberculosis 1

Drugs for Mycobacterium Tuberculosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 544)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium carbonate Approved, Investigational Phase 4 471-34-1
2
Lumefantrine Approved Phase 4 82186-77-4 6437380
3
Artemether Approved Phase 4 71963-77-4 68911 119380
4
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
5
Dapsone Approved, Investigational Phase 4 80-08-0 2955
6
Sulfamethoxazole Approved Phase 4 723-46-6 5329
7
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
8
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
9
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
10
Ustekinumab Approved, Investigational Phase 4 815610-63-0
11
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
12
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
13 Brodalumab Approved, Investigational Phase 4 1174395-19-7
14
Halofantrine Approved Phase 4 69756-53-2 37393
15
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
16
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
17
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
18
Bisoprolol Approved Phase 4 66722-44-9 2405
19
Budesonide Approved Phase 4 51333-22-3 63006 5281004
20
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
21
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
22
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
23
Bedaquiline Approved Phase 4 843663-66-1
24
Ofloxacin Approved Phase 4 82419-36-1 4583
25
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
26
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
27
Methadone Approved, Illicit Phase 4 76-99-3 4095
28
Ethambutol Approved Phase 4 74-55-5 3279 14052
29
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
30
Streptomycin Approved, Vet_approved Phase 4 57-92-1 19649
31
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
32
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
33
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
34
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
35
Prothionamide Approved, Investigational Phase 4 14222-60-7 666418
36
Kanamycin Approved, Investigational, Vet_approved Phase 4 59-01-8, 8063-07-8 6032
37
Cycloserine Approved Phase 4 68-41-7 6234 401
38
Capreomycin Approved Phase 4 11003-38-6 3000502
39
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
40
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
41
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 64778 441130
42
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
43
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
44
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
45
Ethionamide Approved Phase 4 536-33-4 2761171
46
Tofacitinib Approved, Investigational Phase 4 477600-75-2
47
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
48
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
49
Cobicistat Approved Phase 4 1004316-88-4
50
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515

Interventional clinical trials:

(show top 50) (show all 1390)
# Name Status NCT ID Phase Drugs
1 The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis Patients Unknown status NCT02477852 Phase 4 Isoniazid;Rifampicin;Ethambutol;Pyrazinamide
2 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
3 The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing Unknown status NCT01135043 Phase 4
4 The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis Unknown status NCT00728546 Phase 4 Isoniazid (Rifinah)
5 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases Unknown status NCT02464683 Phase 4
6 Randomized, Controlled Trial Comparing Efficacy of Percutaneous and Intradermal Vaccination With Japanese (Tokyo) 172 BCG in the Prevention of Tuberculosis In Infants Vaccinated at Birth Unknown status NCT00242047 Phase 4
7 International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
8 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
9 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
10 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
11 New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
12 Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial Unknown status NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
13 Phase IV Study of the Quantiferon-RD1 Test Unknown status NCT00311220 Phase 4 tuberculin for skin test
14 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
15 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
16 the Safety and Effect in TB Patients With NAC Unknown status NCT02889757 Phase 4 Acteylcysteine
17 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
18 Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau Unknown status NCT02953327 Phase 4
19 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
20 Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial Unknown status NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
21 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial Unknown status NCT02169570 Phase 4
22 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
23 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
24 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
25 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
26 Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) Completed NCT00495339 Phase 4 Levofloxacin
27 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
28 Cost-effectiveness of Quantiferon Gold in VITRO Test of T-lymphocytic Response for Detection of Latent Tuberculosis in At-risk Healthcare Workers Completed NCT00797836 Phase 4
29 Comparison of Two Strategies for Therapeutic Decision-making in Tuberculosis Contact Tracing: a Standard Strategy Based on Tuberculin Skin Test (TST) Alone vs TST Combined With QuantiFERON®-TB Gold In-Tube (QFT-IT) Completed NCT01223534 Phase 4 Preventive treatment with Isoniazid.;Preventive treatment with Isoniazid
30 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
31 A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana Completed NCT00164281 Phase 4 Isoniazid
32 Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation Completed NCT00402402 Phase 4
33 The Pharmacokinetic Effect of Clarithromycin on the AUC0-12h of Linezolid in Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) Patients Completed NCT01521364 Phase 4 Addition of different doses of clarithromycin.
34 A Pilot Study Of Open-Label Fixed Dose Combination Zidovudine/Lamivudine/Abacavir In HIV-Infected Persons With Tuberculosis In Moshi, Tanzania; Tuberculosis And HIV Immune Reconstitution Syndrome Trial (THIRST) Completed NCT00851630 Phase 4 Fixed dose combination zidovudine/lamivudine/abacavir
35 Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis Completed NCT00402454 Phase 4 isoniazid, rifampin + isoniazid or rifampin + pyrazinamide
36 Evaluation of 2 Interferon γ Assays (QuantiFERON TB Gold In-Tube® and T-SPOT.TB®) in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
37 Effect of HIV and/or Active Tuberculosis on the Humoral and Cell Mediated Immune Responses to Un-adjuvanted Trivalent Sub-unit Influenza Vaccine (TIV) in Adults Completed NCT01811823 Phase 4
38 Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB Completed NCT00293228 Phase 4 Isoniazid;isoniazid
39 Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) Completed NCT01637558 Phase 4 8 hourly LPV/r during TB treatment;Nevirapine;Lopinavir/Ritonavir
40 Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial Completed NCT01363765 Phase 4
41 Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity Completed NCT00405301 Phase 4 Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
42 An Evaluation of the Pharmacological Interaction of Lopinavir 800mg - Ritonavir 200mg Combination and Rifampin in Subjects Presenting Tuberculosis, With Contraindication for Antiretroviral Regimens Including Efavirenz Completed NCT00771498 Phase 4 Lopinavir
43 A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa. Completed NCT02348177 Phase 4 lopinavir with ritonavir in 1:1 ratio;Lopinavir/ritonavir 4:1
44 A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy Completed NCT00402610 Phase 4 isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment
45 Impact of TB Preventive Therapy for HIV/TB Co-infected Patients With Access to Highly Active Antiretroviral Therapy in Rio de Janeiro, Brazil: A Phased Implementation Trial Completed NCT00107887 Phase 4 INH preventive therapy;TST (tuberculin skin test)
46 Population Pharmacokinetics Analysis of Ethambutol in Overweight and Obese Volunteers Completed NCT01048697 Phase 4 Ethambutol
47 A Pilot Clinical Trial Characterizing Use of Ingestion Sensor Enabled Rifamate in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis Completed NCT01960257 Phase 4
48 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
49 A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3 Completed NCT00108862 Phase 4
50 Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal Completed NCT00412009 Phase 4

Search NIH Clinical Center for Mycobacterium Tuberculosis 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amikacin
aminosalicylic acid
Aminosalicylic acid
Antitubercular Agents
Bacillus calmette-guerin substrain tice live antigen
Capreomycin
Cortisone acetate
Dexamethasone
Ethambutol
Ethambutol Hydrochloride
Ethionamide
Ethionamide
isoniazid
Isoniazid
Levofloxacin
Methylprednisolone
Prednisolone
Pyrazinamide
Pyrazinamide
Rifabutin
Rifapentine
Streptomycin
Triamcinolone
Tuberculin Purified Protein Derivative

Cochrane evidence based reviews: tuberculoma

Genetic Tests for Mycobacterium Tuberculosis 1

Anatomical Context for Mycobacterium Tuberculosis 1

The Foundational Model of Anatomy Ontology organs/tissues related to Mycobacterium Tuberculosis 1:

19
Brain, Lungs, Lymph Nodes, Pericardium, Pleura, Gastrointestinal Tract

MalaCards organs/tissues related to Mycobacterium Tuberculosis 1:

41
Testes, Lung, Skin, Bone, Breast, Kidney, Lymph Node

Publications for Mycobacterium Tuberculosis 1

Articles related to Mycobacterium Tuberculosis 1:

(show top 50) (show all 31220)
# Title Authors PMID Year
1
Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. 9 8
10882571 2000
2
CISH and susceptibility to infectious diseases. 71
20484391 2010
3
Diagnostic value of polymerase chain reaction/acid-fast bacilli in conjunction with computed tomography-guided pleural biopsy in tuberculous pleurisy: A diagnostic accuracy study. 17
31335667 2019
4
Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis. 17
31199047 2019
5
IP-10 for the diagnosis of tuberculosis in children: Protocol for a systematic review and meta-analysis. 17
31169732 2019
6
The Mycobacterium tuberculosis cytochrome P450 system. 9 38
19635450 2010
7
TNF in host resistance to tuberculosis infection. 9 38
20173394 2010
8
cAMP signaling in Mycobacterium tuberculosis. 9 38
19634702 2009
9
Structure-activity relationships of compounds targeting mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate synthase. 9 38
18783951 2008
10
Interferon gamma assays for tuberculosis in children. 9 38
18846802 2008
11
IL-23 and IL-17 in tuberculosis. 9 38
18218322 2008
12
CD209 genetic polymorphism and tuberculosis disease. 9 38
18167547 2008
13
Host innate immune response to Mycobacterium tuberculosis. 9 38
17364232 2007
14
Tumor necrosis factor and tuberculosis. 9 38
17502865 2007
15
Th2 cytokines in susceptibility to tuberculosis. 9 38
17504117 2007
16
Mycobacterium tuberculosis complex in atherosclerosis. 9 38
16418767 2005
17
The unusual chaperonins of Mycobacterium tuberculosis. 9 38
16253564 2005
18
Protective responses in tuberculosis: induction of genes for interferon-gamma and cytotoxicity by Mycobacterium tuberculosis and during human tuberculosis. 9 38
15320888 2004
19
Metabolism of 2-methyladenosine in Mycobacterium tuberculosis. 9 38
15207808 2004
20
[Tuberculosis in compromised hosts]. 9 38
14672050 2003
21
Mannose-binding lectin polymorphisms in clinical tuberculosis. 9 38
12934195 2003
22
[Serum adenosine deaminase activity in pulmonary tuberculosis]. 9 38
15143406 2003
23
[Up-to-date understanding of tuberculosis immunity]. 9 38
12683337 2003
24
Genetic basis of tuberculosis susceptibility in India. 9 38
12501922 2002
25
P2X7 receptors and apoptosis in tuberculosis infection. 9 38
11693438 2001
26
Advances in the immunopathogenesis of pulmonary tuberculosis. 9 38
11371766 2001
27
Production of interleukin-18 in human tuberculosis. 9 38
10882602 2000
28
Human genetic susceptibility to tuberculosis. 9 38
10976382 2000
29
The NRAMP1 gene and susceptibility to tuberculosis. 9 38
9669915 1998
30
The NRAMP1 gene and susceptibility to tuberculosis. 9 38
9669916 1998
31
Host genetic susceptibility to human tuberculosis. 9 38
9949798 1998
32
[Construction of mycobacterium tuberculosis genomic library]. 9 38
10072801 1997
33
Alcohol, tumor necrosis factor, and tuberculosis. 9 38
7771645 1995
34
Mycobacterium tuberculosis expresses two chaperonin-60 homologs. 9 38
7681982 1993
35
Chronic foot pain, an atypical tuberculosis presentation. 38
31257061 2019
36
Calcitriol enhances pyrazinamide treatment of murine tuberculosis. 38
31425356 2019
37
Individualising therapy for drug-sensitive tuberculosis. 38
31427253 2019
38
Managing tuberculosis in the Baltic states. 38
31221567 2019
39
Macrophage heterogeneity and plasticity in tuberculosis. 38
30938876 2019
40
Genetics and roadblocks of drug resistant tuberculosis. 38
30261266 2019
41
8-Hydroxyquinolines are bactericidal against Mycobacterium tuberculosis. 38
30893501 2019
42
Oxadiazole scaffolds in anti-tuberculosis drug discovery. 38
31296357 2019
43
The hidden hypothesis: A disseminated tuberculosis case. 38
31150844 2019
44
Multimodal imaging of fibrosing mesenteric tuberculosis. 38
31193572 2019
45
Insights and challenges in tuberculosis vaccine development. 38
31416767 2019
46
Update in Lung Infections and Tuberculosis 2018. 38
31042415 2019
47
Tuberculosis Control: WHO Perspective and Guidelines. 38
31240568 2019
48
New Perspectives in Latent Tuberculosis Infection. 38
31405608 2019
49
The burden of latent multidrug-resistant tuberculosis. 38
31281060 2019
50
Hodgkin lymphoma, tuberculosis and atypical radiologic image 38
31387344 2019

Variations for Mycobacterium Tuberculosis 1

ClinVar genetic disease variations for Mycobacterium Tuberculosis 1:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CISH NM_001243926.1(MAPKAPK3): c.-436A> T single nucleotide variant risk factor rs414171 3:50649499-50649499 3:50612068-50612068

Expression for Mycobacterium Tuberculosis 1

Search GEO for disease gene expression data for Mycobacterium Tuberculosis 1.

Pathways for Mycobacterium Tuberculosis 1

Pathways related to Mycobacterium Tuberculosis 1 according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TNF TLR2 SLC11A1 IL4 IL17A IL12RB1
2
Show member pathways
13.52 TNF IL4 IL17A IL12RB1 IL10 IFNGR1
3
Show member pathways
13.33 TNF IL4 IL17A IL12RB1 IL10 IFNGR1
4
Show member pathways
13.09 TNF TLR2 IL10 IFNGR1 IFNG CISH
5
Show member pathways
12.84 TNF IL4 IL17A IL12RB1 IL10 IFNGR1
6
Show member pathways
12.6 TNF IL4 IL12RB1 IL10 IFNGR1 IFNG
7
Show member pathways
12.57